Next 10 |
I-MAB Filed 2023 Annual Report on Form 20-F PR Newswire ROCKVILLE, Md. , April 30, 2024 /PRNewswire/ -- I-Mab (the "Company") (NASDAQ: IMAB), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of...
I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference PR Newswire ROCKVILLE, Md. , April 5, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a U.S.-based, global biotech company, exclusively focused on the development and potential commercializa...
I-Mab Announces Closing of the Divestiture of Business Operations in China PR Newswire ROCKVILLE, Md. , April 2, 2024 /PRNewswire/ -- I-Mab (the " Company ") (NASDAQ: IMAB) a U.S.-based, global biotech company, exclusively focused on the development and ...
China Resources Beer (Holdings) Company Limited ADR (CRHKY) is expected to report for Q4 2023 Melco International Development Ltd. (MDEVF) is expected to report for quarter end 2023-12-31 Meridian Mining UK Societas (MRRDF) is expected to report $0 for Q4 2023 BKF Capital Group Inc (B...
2024-03-18 10:15:04 ET Piper Sandler analyst issues OVERWEIGHT recommendation for IMAB on March 18, 2024 07:52AM ET. The previous analyst recommendation was Overweight. IMAB was trading at $1.75 at issue of the analyst recommendation. The overall analyst consensus : BUY....
2024-03-14 17:11:38 ET More on I-Mab Biopharma I-Mab: Trading Below Net Cash With Multiple Upside Options I-Mab to divest Chinese assets amid rising geopolitical tensions Read the full article on Seeking Alpha For further details see: I-Mab Biopharma GAAP...
I-Mab Reports Full Year 2023 Financial Results and Business Update PR Newswire Recently announced agreement to divest assets and business operations in China marks an important milestone for the Company; the transaction is expected to close by the end of March 2024 ...
2024-02-18 03:28:21 ET Summary I-Mab Biopharma has signed an agreement to divest its assets and business operations in China, becoming a US-based biotech company. The divesting will provide I-Mab with a healthy balance sheet, over $400 million in cash, and the potential to receive...
2024-02-11 01:25:00 ET Summary I-Mab Hangzhou will acquire rights to I-Mab’s drug assets in Greater China for $80 M. Anbogen Therapeutics raised $12.5M in a Series A funding round. to advance its two lead drug candidates. Bayer signed a non-binding Letter of Intent to m...
2024-02-07 11:28:54 ET More on I-Mab Biopharma Seeking Alpha’s Quant Rating on I-Mab Biopharma Historical earnings data for I-Mab Biopharma Financial information for I-Mab Biopharma Read the full article on Seeking Alpha For further details see...
News, Short Squeeze, Breakout and More Instantly...
I-MAB Company Name:
IMAB Stock Symbol:
NASDAQ Market:
I-MAB Filed 2023 Annual Report on Form 20-F PR Newswire ROCKVILLE, Md. , April 30, 2024 /PRNewswire/ -- I-Mab (the "Company") (NASDAQ: IMAB), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of...
I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference PR Newswire ROCKVILLE, Md. , April 5, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a U.S.-based, global biotech company, exclusively focused on the development and potential commercializa...
I-Mab Announces Closing of the Divestiture of Business Operations in China PR Newswire ROCKVILLE, Md. , April 2, 2024 /PRNewswire/ -- I-Mab (the " Company ") (NASDAQ: IMAB) a U.S.-based, global biotech company, exclusively focused on the development and ...